You are here

Home » Content

KRONİK DİYALİZ HASTALARINDA HEPATİT G VİRÜS ENFEKSİYONU

HEPATITIS G VIRUS INFECTION IN CHRONIC DIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2001

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Recently a new human hepatitis virus was identified. Hepatitis G virus (HGV) can be transmitted parenterally. Patients on hemodialysis (HD) have been shown to be at increased risk of this new virus. Whether continuous ambulatory peritoneal dialysis (CAPD) can reduce the risk of HGV infection as demonstrated for patients hepatitis C virus (HCV) remains unknown. We studied 67 hemodialysis patients and 53 CAPD patients to evaluate prevalence, risk factors, and clinical manifestations of HGV infection in the dialysis population. 200 healthy adults were selected as controls. In all cases, HGV-RNA was determined with reverse transcriptase method using polymerase chain reaction. The prevalence of HGV viraemia in CAPD patients was 5.6%, compared with 0.5% of healthy adults (p<0.05). But, the frequency in hemodialysis patients (31.3%) was higher than the other two groups. HGV RNA was positive in 36% of HD patients and 6.4% ofCAPD patients who received blood transfusion previously (p<0.01). The frequency of anti-HCV antibody was significantly higher in HGV-positive than HGV-negative patients (16/24 (66.6%) vs 28/96 (29%), p<0.01). In addition, HGV-positive patients had higher dialysis duration than HGV-negative patients. Among the 21 HGV-positive HD and 3 CAPD patients only six of them had high serum ALT levels in different ranges, 16 of them were positive for anti-HCV and 6 for HCV RNA. There was no correlation betwen sex, patient age, ALT levels and blood transfusion amounts with the frequency of HGV-RNA in the patients with HGV viraemia, but only was positive correlated with dialysis duration (r = 0.2726, p:0.0026). As a result, we came to the conclusion that the risk of HGVviraemia in dialysis patients increased, more marked in HD patients. But it will be useful to planned more long-term follow-up studies investigating the transmission, routes and clinical importance of HGV, and the relationship with other viruses
Bookmark/Search this post with
Abstract (Original Language): 
Son zamanlarda, yeni bir insan hepatiti virusu tanımlanmıştır. Hepatit G virusu (HGV) parenteral olarak bulaşabilir. Hemodiyaliz (HD) hastalarında bu yeni virus riskinin artmış olduğu gösterilmiştir. Sürekli ayaktan periton diyalizi'nin (SAPD) hepatit C virusu (HCV) hastalarında/d gibi HGV enfeksiyonu riskini de azaltıp azaltmayacağı bilinmemektedir. Biz diyaliz popülasy onunda HGV enfeksiyonu prevalansını, risk faktörlerini ve klinik bulgularını değerlendirmek için 67HD ve 53 SAPD hastasını inceledik. 200 sağlıklı erişkin kontrol grubu olarak seçildi. Tüm olgularda HGV-RNA reverse transcriptase metodu kullanılarak polymerase chain reaction (PCR) ile saptandı. HGV viremisi prevalansı SAPD hastalarında sağlıklı bireylerin %0.5'lik oranıyla kıyaslandığında %5.6 idi (p<0.05). Ama, HD hastalarında sıklık (%3l.3J diğer iki gruptan daha yüksekti. Kan transfüzyonu yapılan HD hastalarının %36'sında SAPD hastalarının %6.4'ünde HGV RNA pozitifti (p<0.01). anti-HCV sıklığı HGV-pozitif hastalarda HGV-negatif hastalardan anlamlı daha yüksekti (16/24(66.6%) vs 28/96(29%),p<0.01). Ayrıca, HGV-pozitif hastalar negatif hastalara göre daha uzun diyaliz süresine sahiptiler. HGV-pozitif 21 HD ve 3 SAPD hastasının sadece 6'sında serum ALT düzeyleri farklı oranlarda yüksekti ve bu hastaların 16'sında anti-HCVve 6'sında HCV RNA pozitifti. HGV RNA sıklığı ile cinsiyet, hasta yaşı, serum Al,T düzeyleri ve kan transfüzyon miktarları arasında korelasyon yoktu, ama sadece diyaliz süresi ile anlamlı pozitif ilişki mevcuttu (r = 0.2726, p:0.0026). Sonuçta HD hastalarında daha belirgin olmak üzere diyaliz hastalarında HGV viremi riskinin arttığı kanaatine vardık. Fakat, bu hastalarda bulaş yolları, HGV'nin klinik önemi ve diğer viruslarla ilişkisini araştıran daha uzun süreli çalışmaların planlanması yararlı olacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_345.pdf
  • 3
162-167
  • Turkish

REFERENCES

References: 

1. Alter MJ, Gallagher M, Morris TT et al. Acute non-A-E hepatitis in the United States and role of hepatitis G virus infection. N Engl J Med. 1997; 336: 741-746.
2. Alter MJ, Margolis HS, Krawczynski K et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B
hepatitis study team. N Engl J Med 1992; 327: 1899¬1905.
3. Linnen J, Wages J, Zhen-Yong ZK et al. Hepatitis G. A virus in search of a disease. Hepatology 1996; 24: 461 -
463.
4. Leary TP, Mue'rhoff AS, Simons JN et al. Sequence and genomic organisation of GBV-C: a novel member of the Flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996;48:60-67.
5. Linnen J, Wages J, Zhang-Keck Z-Y et al. Molecular cloning and disease association of hepatitis G virus: A tranfussion-tranmissibl agent. Science 1996; 271: SOS-SOS.
6. Zuckerman AJ. Alphabet of hepatitis viruses. Lancet
1996; 347: 558-559.
7. Schmidt B, Korn K, Fleckenstein B. Molecular evidence for transmission of hepatitis G virus by blood
transfusion. Lancet 1996; 347: 909.
8. Tacke M, Kiyosawa K, Stark K et al. Detection of antibodies to putative hepatitis G virus envelope protein.
Lancet 1997; 349: 318-321.
9. Dille BJ, Suowy TK, Gutierez RA ct at. An EL1SA for GB virus C. J Infect Dis 1997; 175: 458-461.
10. Dawson GJ, Schlauder GG, Pilot-Matrias TJ et al.
Prevalence studies of GB virus C infection using reverse transcriptase polymerase chain reaction. J Med Virol
1996;50:97-103.
11. Alter HJ, Nakatsuji Y, Melpolder J et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336: 747-754.
12.
Ülge
n SK, Avşar W, Ovalı E ve ark. Kemik iliği transplantasyonu uygulanmış olgularda HGV seroprevalansı ve HGV enfeksiyonunu önemi. 14.UGK, 28 Eylül-3 Ekim 1997, Mersin, Türk Gastroenteroloji
Dergisi 1997; 8 (suppl 1): A34.
13. Sheng L, Widyastati K, Kosala H et al. High prevalence . of a hepatitis virus infection compared with hepatitis C virus in patients undergoing chronic hemodialysis. Am J Kidney Dis 1998;31:218-223.
14. Kallinowski B, Ahmedi R, Seipp S, Bommcr J, Stremmel W. Clinical impact of GB-C virus in hemodialysis patients, Nephrol Dial Transplant 1998;
13: 93-98.
15. Forns X, Ferrandez L-P, Costa J et al. Hepatitis G virus infection in a hemodialysis unit: Prevalence and clinical
implication. Nephrol Dial Transplant 1997; 12: 956-960.
166
16. Loisseau P, Mariotti M, Corbi C et al. Prevalence of hepatitis G virus RNA in French donors and recipients, Transfussion 1997; 37: 645-650.
17. Mazzoni A, Innocenti M, Consaga M. Retrospective study on the prevalence of B and non-A, non-B hepatitis in a dialysis unit: 17-year follow-up. Nephron 1992; 61: 316-317.
18. Masuko K, Mitsui T, Iwano K et al. Infection with hepatitis GB virus C in patients on maintenance
hemodialysis. N Engl J Med 1996; 334: 1485-1490.
19. de Lamballerie X, Charrel RN. Hepatitis GB virus C in patients on hemodialysis. Lancet !996; 334: 1549.
20.
Yavu
z M, Ersoy A, Güllülü M ve ark. Sürekli Ayaktan Periton Diyalizi (SAPD) Hastalarında Hepatit B ve Hepatit C Prevalansı ve Risk Faktörleri: Bir SAPD Ünitesinin 6 Yıllık Verileri. Bursa Devlet Hastanesi
Bülteni 2000; 16(1): 43-46.
21.
Szab
o A, Viazov S, Heemann U et al. GBV-C/HGV infection in renal dialysis and transplant patient. Nephrol
Dial Transplant 1997; 12: 2380-2384.
22. Cornu C, Jadoul M, Loutc G, Goubau P. Hepatitis G virus infection in haemodialysed patients: epidemiology and clinical relevance. Nephrol Dial Transplant 1997;
12: 1326-1329.
23. Sampietro M, Badalamenti S, Graziani G et al. Hepatitis G virus infection in hemodialysis patients. Kidney Int 1997;51:348-352.
24. Tribl B, Oesterreicher C, Pohanka E et ai. GBV-C/HGV
in hemodialysis patients: Anti-E2 antibodies and GBV-C/RNA in serum and peripheral blood mononuclear
cells. Kidney Int 1998; 53: 212-216.
25. Günaydın M, Bedir A. Akpolat T et al. Prevalence of serum HGV-RNA among hemodialysis patients.
Infection 1997;25:307-309.
26. Huang CH, Kao JH, Kuo YM, Tsai TJ, Hung KY, Chen DS. GB virus C/hcpatitis G virus infection in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial
Transplant 1998; 13: 2914-2919.
27. Noh H, Kang SW, Choi SH et al. Hepatitis G virus
infection in hemodialysis and continuous ambulatory peritoneal dialysis patients. Yonsei Med J 1998; 39: 116-121.
28.
Özene
r İÇ, Geyik G, Bihorav A ve ark. SAPD hastalarında HGV infeksiyonu. Türk Nefroloji Diyaliz
ve Transplantasyon Dergisi 2000; 9(4): 212-214.
29. Schlipköter U, Roggendorf M, Ernst G et al. Hepatitis C
virus antibodies in haemodialysis patients. Lancet 1990;
335: 1409.
30. Okamoto H, Nakao H, Inoue T et al. The entire nucleotide sequnce of two GB virus C/hepatitis G virus isolates of distinct genotypes from Japan. J Gen Virol
1997;78:737-745.
31. Erensoy S. HGV enfeksiyonu. Viral Hepatit 98. Ed. Kılıçturgay K. Viral Hepatitle Savaşım Derneği. Deniz
Ofset, İstanbul, 1998:204-211.
32. Fabrizi F, Lunghi G, Bacchini G et al. Hepatitis G virus infection in chronic dialysis patients and kidney transplant recipient. Nephrol Dial Transplant 1997; 12: 1645-1651.
33. Guh JY, Lai YH, Yang CY et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995; 69: 459-465.
34. loisseau P, Mariotti M, Corbi C et al. Prevalence of hepatitis G virus RNA in French donors and recipients.
Transfussion 1997; 37: 645-650.
107

Thank you for copying data from http://www.arastirmax.com